A new study, conducted by researchers from the The Hague Institute of Immunology in California, found that the body makes a strong immune response after fighting the emerging corona virus.
Alessandro Seet, a professor with the Center for Infectious Diseases and Vaccines Research and author of the research paper, which was published in the journal Cel, explained: “If we had seen weak marginal immune responses we would have worried, but we have seen T cells (a cell type that plays an immune role in the immune response) a strong response against the viral thorn protein, which is The goal of most ongoing efforts, and other viral proteins.
The study included 20 people who recovered from Covid-19, and it was conducted to enable researchers to fully understand how the body develops immunity to the virus, in order to be able to make an effective vaccine; So, Cit said, "This discovery is very promising when it comes to making a vaccine."
Researchers from all over the world agreed that the thorn protein is the source of the ability of the Corona virus to invade human cells, as it binds to their receptors and fuses with their membranes, entering the virus in them.
"We deliberately studied those who had a normal course of illness, and did not need hospitalization, to come up with a strict standard for the nature of the normal immune response," Seet added. Because the virus in some cases leads to exceptional symptoms ».
T cells in the 20 people had a healthy response, helping their bodies generate antibodies that killed HIV-infected cells.
In a more clear statement, the researchers identified "CD4 helper T cells interacting with SARS-Cove-2", which contributed to confronting it. In another experiment, researchers found these specific T cells in 40 to 60% of people who were not exposed to this virus, but who were exposed to other "zakkam" viruses.
This suggests that before the SARS-Cove-2 outbreak developed an immune response that might help them cope, researchers nevertheless noted that we are still at the beginning of the road.